NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announces that it has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable the pharmaceutical and life science industries to advance discoveries and deliver groundbreaking treatments to patients. Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia. NAMSA is an ARCHIMED company; acquired by the healthcare-focused global private equity firm in 2020. The acquisition of WuXi AppTec’s U.S. Medical Device Testing Operations is the 9th acquisition by NAMSA since becoming an ARCHIMED company.
Read the full article: NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying Its Position as the Leader in MedTech Testing and Clinical Research //
Source: https://www.businesswire.com/news/home/20250117736171/en/NAMSA-Acquires-the-U.S.-Medical-Device-Testing-Operations-of-WuXi-AppTec-Solidifying-its-Position-as-the-Leader-in-MedTech-Testing-and-Clinical-Research